RUBY dMMR Post Hoc Analysis
RUBY Post Hoc Analysis: Survival Outcomes With Dostarlimab Plus Chemotherapy by Type of MMR Deficiency in Patients With Endometrial Cancer

Released: June 25, 2024

Expiration: June 24, 2025

Activity

Progress
1
Course Completed